Monali Patil1, Samjot Singh Dhillon2, Kristopher Attwood3, Marwan Saoud4, Abdul Hamid Alraiyes2, Kassem Harris5. 1. Department of Pulmonary, Critical Care and Sleep Medicine, State University of New York (SUNY) at Buffalo, Buffalo, NY. 2. Department of Pulmonary, Critical Care and Sleep Medicine, State University of New York (SUNY) at Buffalo, Buffalo, NY; Department of Medicine, Pulmonary Medicine, and Interventional Pulmonary Section, Roswell Park Cancer Institute, Buffalo, NY. 3. Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY. 4. Department of Internal Medicine, State University of New York (SUNY) at Buffalo, Buffalo, NY. 5. Department of Pulmonary, Critical Care and Sleep Medicine, State University of New York (SUNY) at Buffalo, Buffalo, NY; Department of Medicine, Pulmonary Medicine, and Interventional Pulmonary Section, Roswell Park Cancer Institute, Buffalo, NY. Electronic address: kassemharris@gmail.com.
Abstract
BACKGROUND: The indwelling pleural catheter (IPC), which was initially introduced for the management of recurrent malignant effusions, could be a valuable management option for recurrent benign pleural effusion (BPE), replacing chemical pleurodesis. The purpose of this study is to analyze the efficacy and safety of IPC use in the management of refractory nonmalignant effusions. METHODS: We conducted a systematic review and meta-analysis on the published literature. Retrospective cohort studies, case series, and reports that used IPCs for the management of pleural effusion were included in the study. RESULTS: Thirteen studies were included in the analysis, with a total of 325 patients. Congestive heart failure (49.8%) was the most common cause of BPE requiring IPC placement. The estimated average rate of spontaneous pleurodesis was 51.3% (95% CI, 37.1%-65.6%). The estimated average rate of all complications was 17.2% (95% CI, 9.8%-24.5%) for the entire group. The estimated average rate of major complications included the following: empyema, 2.3% (95% CI, 0.0%-4.7%); loculation, 2.0% (95% CI, 0.0%-4.7%); dislodgement, 1.3% (95% CI, 0.0%-3.7%); leakage, 1.3% (95% CI, 0.0%-3.5%); and pneumothorax, 1.2% (95% CI, 0.0%-4.1%). The estimated average rate of minor complications included the following: skin infection, 2.7% (95% CI, 0.6%-4.9%); blockage and drainage failure, 1.1% (95% CI, 0.0%-3.5%); subcutaneous emphysema, 1.1% (95% CI, 0.0%-4.0%); and other, 2.5% (95% CI, 0.0%-5.2%). One death was directly related to IPC use. CONCLUSIONS: IPCs are an effective and viable option in the management of patients with refractory BPE. The quality of evidence to support IPC use for BPE remains low, and high-quality studies such as randomized controlled trials are needed.
BACKGROUND: The indwelling pleural catheter (IPC), which was initially introduced for the management of recurrent malignant effusions, could be a valuable management option for recurrent benign pleural effusion (BPE), replacing chemical pleurodesis. The purpose of this study is to analyze the efficacy and safety of IPC use in the management of refractory nonmalignant effusions. METHODS: We conducted a systematic review and meta-analysis on the published literature. Retrospective cohort studies, case series, and reports that used IPCs for the management of pleural effusion were included in the study. RESULTS: Thirteen studies were included in the analysis, with a total of 325 patients. Congestive heart failure (49.8%) was the most common cause of BPE requiring IPC placement. The estimated average rate of spontaneous pleurodesis was 51.3% (95% CI, 37.1%-65.6%). The estimated average rate of all complications was 17.2% (95% CI, 9.8%-24.5%) for the entire group. The estimated average rate of major complications included the following: empyema, 2.3% (95% CI, 0.0%-4.7%); loculation, 2.0% (95% CI, 0.0%-4.7%); dislodgement, 1.3% (95% CI, 0.0%-3.7%); leakage, 1.3% (95% CI, 0.0%-3.5%); and pneumothorax, 1.2% (95% CI, 0.0%-4.1%). The estimated average rate of minor complications included the following: skin infection, 2.7% (95% CI, 0.6%-4.9%); blockage and drainage failure, 1.1% (95% CI, 0.0%-3.5%); subcutaneous emphysema, 1.1% (95% CI, 0.0%-4.0%); and other, 2.5% (95% CI, 0.0%-5.2%). One death was directly related to IPC use. CONCLUSIONS: IPCs are an effective and viable option in the management of patients with refractory BPE. The quality of evidence to support IPC use for BPE remains low, and high-quality studies such as randomized controlled trials are needed.
Authors: Samira Shojaee; Najib Rahman; Kevin Haas; Ryan Kern; Michael Leise; Mohammed Alnijoumi; Carla Lamb; Adnan Majid; Jason Akulian; Fabien Maldonado; Hans Lee; Marwah Khalid; Todd Stravitz; Le Kang; Alexander Chen Journal: Chest Date: 2018-08-29 Impact factor: 9.410
Authors: Rachelle Asciak; Rachel M Mercer; Robert J Hallifax; Maged Hassan; Eihab Bedawi; David McCracken; Nikolaos I Kanellakis; John M Wrightson; Ioannis Psallidas; Najib M Rahman Journal: ERJ Open Res Date: 2019-02-01
Authors: Nikolaj Frost; Christoph Ruwwe-Glösenkamp; Matthias Raspe; Martin Brünger; Bettina Temmesfeld-Wollbrück; Norbert Suttorp; Martin Witzenrath Journal: BMJ Open Respir Res Date: 2020-01